Hemostemix (CVE:HEM) Trading Up 31% – Should You Buy?

by · The Markets Daily

Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price was up 31% during mid-day trading on Friday . The stock traded as high as C$0.23 and last traded at C$0.19. Approximately 480,687 shares were traded during trading, a decline of 9% from the average daily volume of 525,664 shares. The stock had previously closed at C$0.15.

Hemostemix Price Performance

The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The firm has a 50-day moving average of C$0.20 and a 200-day moving average of C$0.12. The stock has a market cap of C$27.69 million, a PE ratio of -5.54 and a beta of 0.20.

About Hemostemix

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

Read More